Summary
36.25 0.48(1.34%)10/04/2024
Enact Holdings Inc (ACT)
Enact Holdings Inc (ACT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.31 | 0.11 | 1.74 | 18.97 | 18.58 | 32.06 | 0.00 | -25.18 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 36.25 | |
| Open | 36.07 | |
| High | 36.33 | |
| Low | 35.93 | |
| Volume | 248,788 | |
| Change | 0.47 | |
| Change % | 1.31 | |
| Avg Volume (20 Days) | 252,205 | |
| Volume/Avg Volume (20 Days) Ratio | 0.99 | |
| 52 Week Range | 26.13 - 37.09 | |
| Price vs 52 Week High | -2.26% | |
| Price vs 52 Week Low | 38.73% | |
| Range | 0.50 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 5,653 | |
| EBIDTA | 0 | |
| PE Ratio | 7.0007 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 25.42 | |
| Book Value | 25.8010 | |
| Earnings Per Share | 2.9740 | |
| EPS Estimate Current Quarter | 0.8100 | |
| EPS Estimate Next Quarter | 0.8200 | |
| EPS Estimate Current Year | 3.2600 | |
| EPS Estimate Next Year | 3.4200 | |
| Diluted EPS (TTM) | 2.9740 | |
| Revenues | ||
| Profit Marging | 0.4284 | |
| Operating Marging (TTM) | 0.5909 | |
| Return on asset (TTM) | 0.0726 | |
| Return on equity (TTM) | 0.1216 | |
| Revenue TTM | 1,130,526,976 | |
| Revenue per share TTM | 6.9430 | |
| Quarterly Revenue Growth (YOY) | -0.0140 | |
| Quarterly Earnings Growth (YOY) | -0.0090 | |
| Gross Profit (TTM) | 490,662,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 7.0007 | |
| Forward PE | 6.1958 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.8066 | |
| Revenue Enterprise Value | 3.4810 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 162,840,000 | |
| Shares Float | 148,025,098 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 81.70 | |
| Institutions (%) | 18.11 | |
09/25 10:46 EST - zacks.com
Is Enact Holdings (ACT) Outperforming Other Finance Stocks This Year?
Here is how Enact Holdings, Inc. (ACT) and Arch Capital Group (ACGL) have performed compared to their sector so far this year.
Is Enact Holdings (ACT) Outperforming Other Finance Stocks This Year?
Here is how Enact Holdings, Inc. (ACT) and Arch Capital Group (ACGL) have performed compared to their sector so far this year.
09/06 03:02 EST - proactiveinvestors.co.uk
7-Eleven owner rejects $38bn takeover bid as it ‘grossly undervalues' business
7-Eleven's Japanese owner Seven & i has formally rejected a takeover bid tabled by Canadian convenience store giant Alimentation Couche-Tard Inc (TSX:ATD.B) (ACT). ACT, which owns the Circle K chain, announced the surprise $38 billion bid in August, in what would have been the largest takeover of a Japanese corporate in history.
7-Eleven owner rejects $38bn takeover bid as it ‘grossly undervalues' business
7-Eleven's Japanese owner Seven & i has formally rejected a takeover bid tabled by Canadian convenience store giant Alimentation Couche-Tard Inc (TSX:ATD.B) (ACT). ACT, which owns the Circle K chain, announced the surprise $38 billion bid in August, in what would have been the largest takeover of a Japanese corporate in history.
09/05 06:30 EST - prnewswire.com
PRIMO WATER AND BLUETRITON BRANDS ANNOUNCE EXPIRATION OF THE WAITING PERIOD UNDER THE HSR ACT
TAMPA, Fla. and STAMFORD, Conn.
PRIMO WATER AND BLUETRITON BRANDS ANNOUNCE EXPIRATION OF THE WAITING PERIOD UNDER THE HSR ACT
TAMPA, Fla. and STAMFORD, Conn.
08/21 18:40 EST - globenewswire.com
Enact Provides Update on Capital Position Under New PMIERs Available Asset Guidelines
RALEIGH, N.C., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact), a leading provider of private mortgage insurance through its insurance subsidiaries, today addressed the updated Private Mortgage Insurer Eligibility Requirements (PMIERs) released by Fannie Mae and Freddie Mac (the GSEs), and the Federal Housing Finance Administration (FHFA) on August 21, 2024 which will be phased-in between March 31, 2025 and September 30, 2026.
Enact Provides Update on Capital Position Under New PMIERs Available Asset Guidelines
RALEIGH, N.C., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact), a leading provider of private mortgage insurance through its insurance subsidiaries, today addressed the updated Private Mortgage Insurer Eligibility Requirements (PMIERs) released by Fannie Mae and Freddie Mac (the GSEs), and the Federal Housing Finance Administration (FHFA) on August 21, 2024 which will be phased-in between March 31, 2025 and September 30, 2026.
08/19 17:06 EST - globenewswire.com
Enact Re, Ltd. Receives A- Rating from S&P Global Ratings
First Rating Assigned to Enact Re by S&P and Second Rating Since Launch Underscores Continued Strong Performance First Rating Assigned to Enact Re by S&P and Second Rating Since Launch Underscores Continued Strong Performance
Enact Re, Ltd. Receives A- Rating from S&P Global Ratings
First Rating Assigned to Enact Re by S&P and Second Rating Since Launch Underscores Continued Strong Performance First Rating Assigned to Enact Re by S&P and Second Rating Since Launch Underscores Continued Strong Performance
08/19 10:34 EST - newsfilecorp.com
CSE Bulletin: Consolidation - Aduro Clean Technologies Inc. (ACT)
Toronto, Ontario--(Newsfile Corp. - Le 19 août/August 2024) - Aduro Clean Technologies Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every three and one quarter (3.25) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 27,174,297 common shares.
CSE Bulletin: Consolidation - Aduro Clean Technologies Inc. (ACT)
Toronto, Ontario--(Newsfile Corp. - Le 19 août/August 2024) - Aduro Clean Technologies Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every three and one quarter (3.25) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 27,174,297 common shares.
08/07 06:55 EST - zacks.com
New Strong Buy Stocks for August 7th
GRC, HGTY, APOG, AER and ACT have been added to the Zacks Rank #1 (Strong Buy) List on August 7, 2024.
New Strong Buy Stocks for August 7th
GRC, HGTY, APOG, AER and ACT have been added to the Zacks Rank #1 (Strong Buy) List on August 7, 2024.
08/01 08:00 EST - prnewswire.com
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
- Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs - Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined immunodeficiency disease, β-thalassemia and Fanconi's anemia NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the issuance of U.S. Patent No. 11,912,780 titled, "Anti-CD45-Based Conditioning Methods and Uses Thereof in Conjunction with Gene-Edited Cell Based Therapies" by the United States Patent and Trademark Office (USPTO).
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
- Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs - Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined immunodeficiency disease, β-thalassemia and Fanconi's anemia NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the issuance of U.S. Patent No. 11,912,780 titled, "Anti-CD45-Based Conditioning Methods and Uses Thereof in Conjunction with Gene-Edited Cell Based Therapies" by the United States Patent and Trademark Office (USPTO).
07/31 19:40 EST - zacks.com
Enact Holdings, Inc. (ACT) Surpasses Q2 Earnings Estimates
Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.10 per share a year ago.
Enact Holdings, Inc. (ACT) Surpasses Q2 Earnings Estimates
Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.10 per share a year ago.
07/31 16:15 EST - globenewswire.com
Enact Reports Second Quarter 2024 Results and Announces Quarterly Dividend
GAAP Net Income of $184 million , or $1.16 per diluted share Adjusted Operating Income of $201 million , or $1.27 per diluted share Return on Equity of 15.4% and Adjusted Operating Return on Equity of 16.9% Record Primary insurance in-force of $266 billion , a 3% increase from second quarter 2023 PMIERs Sufficiency of 169% or $2,057 million Book Value Per Share of $30.91 and Book Value Per Share excluding AOCI of $32.43 Announces quarterly cash dividend of $0.185 per common share
Enact Reports Second Quarter 2024 Results and Announces Quarterly Dividend
GAAP Net Income of $184 million , or $1.16 per diluted share Adjusted Operating Income of $201 million , or $1.27 per diluted share Return on Equity of 15.4% and Adjusted Operating Return on Equity of 16.9% Record Primary insurance in-force of $266 billion , a 3% increase from second quarter 2023 PMIERs Sufficiency of 169% or $2,057 million Book Value Per Share of $30.91 and Book Value Per Share excluding AOCI of $32.43 Announces quarterly cash dividend of $0.185 per common share
07/25 08:45 EST - prnewswire.com
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need - Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease patients - Initial trial focused on conditioning for bone marrow transplant intended to inform subsequent gene therapy conditioning study and provide broader access to cellular therapy for sickle cell patients NEW YORK , July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the FDA clearance of an Investigational New Drug (IND) application to study Iomab-ACT for targeted conditioning prior to a bone marrow transplant (BMT), in patients with sickle cell disease. The study will be conducted in collaboration with the Columbia University and led by Markus Mapara, M.D.
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need - Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease patients - Initial trial focused on conditioning for bone marrow transplant intended to inform subsequent gene therapy conditioning study and provide broader access to cellular therapy for sickle cell patients NEW YORK , July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the FDA clearance of an Investigational New Drug (IND) application to study Iomab-ACT for targeted conditioning prior to a bone marrow transplant (BMT), in patients with sickle cell disease. The study will be conducted in collaboration with the Columbia University and led by Markus Mapara, M.D.
07/24 11:06 EST - zacks.com
Enact Holdings, Inc. (ACT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Enact Holdings (ACT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enact Holdings, Inc. (ACT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Enact Holdings (ACT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/21 04:32 EST - seekingalpha.com
Enact Holdings: Defensive Play In A Corner Of The Housing Market
Enact Holdings, a mortgage insurance company, has outperformed the S&P 500 index over a two-year period in spite of low mortgage originations. However, the pace of gains has slowed, and the companies competing in the mortgage insurance sector all appear fairly valued at this time. Enact has shareholder-friendly management with a growing dividend and share repurchases, however opportunity for organic appreciation in the shares may be limited in the near term.
Enact Holdings: Defensive Play In A Corner Of The Housing Market
Enact Holdings, a mortgage insurance company, has outperformed the S&P 500 index over a two-year period in spite of low mortgage originations. However, the pace of gains has slowed, and the companies competing in the mortgage insurance sector all appear fairly valued at this time. Enact has shareholder-friendly management with a growing dividend and share repurchases, however opportunity for organic appreciation in the shares may be limited in the near term.
07/10 13:11 EST - zacks.com
Can Enact Holdings (ACT) Keep the Earnings Surprise Streak Alive?
Enact Holdings (ACT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Enact Holdings (ACT) Keep the Earnings Surprise Streak Alive?
Enact Holdings (ACT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
07/09 09:05 EST - globenewswire.com
Enact to Host Second Quarter 2024 Earnings Call August 1st
RALEIGH, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its second quarter earnings release after the market closes on July 31, 2024. Enact will host a conference call to review second quarter 2024 financial results on August 1, 2024 at 8:00 a.m. (ET).
Enact to Host Second Quarter 2024 Earnings Call August 1st
RALEIGH, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its second quarter earnings release after the market closes on July 31, 2024. Enact will host a conference call to review second quarter 2024 financial results on August 1, 2024 at 8:00 a.m. (ET).
06/27 16:10 EST - globenewswire.com
Enact Completes XOL Reinsurance Transaction as Part of its Diversified Credit Risk Transfer Program
Secures approximately $90 million of excess of loss reinsurance coverage from panel of reinsurers Secures approximately $90 million of excess of loss reinsurance coverage from panel of reinsurers
Enact Completes XOL Reinsurance Transaction as Part of its Diversified Credit Risk Transfer Program
Secures approximately $90 million of excess of loss reinsurance coverage from panel of reinsurers Secures approximately $90 million of excess of loss reinsurance coverage from panel of reinsurers
06/19 10:45 EST - zacks.com
MTG or ACT: Which Multiline Insurance Stock is Better-Positioned?
Let's see how MGIC Investment (MTG) and Enact Holdings (ACT) fare in terms of some of the key metrics.
MTG or ACT: Which Multiline Insurance Stock is Better-Positioned?
Let's see how MGIC Investment (MTG) and Enact Holdings (ACT) fare in terms of some of the key metrics.
06/07 09:16 EST - zacks.com
5 Stocks With Recent Dividend Hikes to Watch
Five stocks with recent dividend hike are: ACT, SEIC, NTAP, RY, DCI.
5 Stocks With Recent Dividend Hikes to Watch
Five stocks with recent dividend hike are: ACT, SEIC, NTAP, RY, DCI.
06/04 08:40 EST - globenewswire.com
Enact to Participate at the 2024 TD Financial Services and Fintech Summit
RALEIGH, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced that the company's President and Chief Executive Officer, Rohit Gupta, will participate in a fireside chat at the 2024 TD Financial Services and Fintech Summit on Thursday, June 6, 2024 at 4:15 pm Eastern Time.
Enact to Participate at the 2024 TD Financial Services and Fintech Summit
RALEIGH, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced that the company's President and Chief Executive Officer, Rohit Gupta, will participate in a fireside chat at the 2024 TD Financial Services and Fintech Summit on Thursday, June 6, 2024 at 4:15 pm Eastern Time.
05/22 18:35 EST - globenewswire.com
Enact Holdings, Inc. Prices $750 Million of Senior Notes
RALEIGH, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact), today announced that it has priced a registered public offering of $750 million of its 6.25% Senior Notes due 2029 (the “2029 Notes”). The expected settlement date for the offering is May 28, 2024, subject to the satisfaction of customary closing conditions.
Enact Holdings, Inc. Prices $750 Million of Senior Notes
RALEIGH, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact), today announced that it has priced a registered public offering of $750 million of its 6.25% Senior Notes due 2029 (the “2029 Notes”). The expected settlement date for the offering is May 28, 2024, subject to the satisfaction of customary closing conditions.